CBU
TSHA icon

CIBC Bancorp USA’s Taysha Gene Therapies TSHA Stock Holding History

CIBC Bancorp USA’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.3K Buy
13,262
+2,141
+19% +$12.7K ﹤0.01% 1862
2026
Q1 		$49.7K Buy
+11,121
New +$51.7K ﹤0.01% 1718
2025
Q3 		$74K Buy
+22,643
New +$64.1K ﹤0.01% 1384

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

CIBC Bancorp USA's TSHA Position: Q2 2026 in Review

CIBC Bancorp USA increased its Taysha Gene Therapies (TSHA) stake by 19% in Q2 2026, buying an estimated $12.7K and bringing the position to 13,262 shares worth $90.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

CIBC Bancorp USA first reported a position in TSHA in Q3 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • CIBC Bancorp USA held 13,262 shares of Taysha Gene Therapies worth $90.3K as of Q2 2026.
  • CIBC Bancorp USA bought 2,141 Taysha Gene Therapies shares in Q2 2026, an estimated $12.7K.
  • Taysha Gene Therapies made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1862 holding.
  • CIBC Bancorp USA first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.